Affimed (NASDAQ:AFMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD) in a report published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

AFMD has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Affimed in a research note on Tuesday, December 10th. Wells Fargo & Company cut their target price on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.50.

Affimed Trading Down 1.3 %

NASDAQ:AFMD opened at $0.62 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. The stock’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $1.85. Affimed has a 52-week low of $0.52 and a 52-week high of $8.95.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in Affimed in the third quarter valued at about $44,000. FMR LLC grew its position in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC grew its position in shares of Affimed by 34.0% during the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 32,053 shares during the period. Northern Trust Corp bought a new stake in shares of Affimed in the 4th quarter valued at about $218,000. Finally, Point72 Asset Management L.P. raised its position in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the period. 30.82% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.